A phase I/II randomized controlled trial PedVacc 002 was conducted to determine the safety and immunogenicity of a single , low dose of MVA.HIVA vaccine delivered intramuscularly to healthy 20-week-old infants born to HIV-1-positive mothers in Nairobi , Kenya .